Loading…
Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors. The company was formerly known as Centry Pharma, Inc. and changed its name to Nuvectis Pharma, Inc. in July 2021. Nuvectis Pharma, Inc. was incorporated in 2020 and is based in Fort Lee, New Jersey.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-28M | $-26M | $-16M | -143.6% | - | 39.2% |
| 2024 | $0M | $-20M | $-19M | $-12M | -195.6% | - | -14.6% |
| 2023 | $0M | $-23M | $-22M | $-16M | -182.4% | - | 16.6% |
| 2022 | $0M | $-19M | $-19M | $-14M | -134.2% | - | - |
| 2021 | - | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 0 | 0 | 0 | 0 |
| Operating Revenue | - | 0 | 0 | 0 | 0 |
| Operating Expense | - | 19.23 | 22.90 | 19.85 | 27.57 |
| Research And Development | - | 13.23 | 15.38 | 12.92 | 18.15 |
| Selling General And Administration | - | 6.01 | 7.52 | 6.93 | 9.42 |
| Total Expenses | - | 19.23 | 22.90 | 19.85 | 27.57 |
| Operating Income | - | -19.23 | -22.90 | -19.85 | -27.57 |
| Total Operating Income As Reported | - | -19.23 | -22.90 | -19.85 | -27.57 |
| EBITDA | - | -19.23 | -22.90 | -19.85 | -27.57 |
| Normalized EBITDA | - | -19.23 | -22.90 | -19.85 | -27.57 |
| EBIT | - | -19.23 | -22.90 | -19.85 | -27.57 |
| Interest Income | - | 0.15 | 0.64 | 0.85 | 1.13 |
| Net Interest Income | - | 0.15 | 0.64 | 0.85 | 1.13 |
| Interest Income Non Operating | - | 0.15 | 0.64 | 0.85 | 1.13 |
| Net Non Operating Interest Income Expense | - | 0.15 | 0.64 | 0.85 | 1.13 |
| Pretax Income | - | -19.08 | -22.26 | -19 | -26.44 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | -19.08 | -22.26 | -19 | -26.44 |
| Net Income From Continuing And Discontinued Operation | - | -19.08 | -22.26 | -19 | -26.44 |
| Net Income From Continuing Operation Net Minority Interest | - | -19.08 | -22.26 | -19 | -26.44 |
| Net Income | - | -19.08 | -22.26 | -19 | -26.44 |
| Net Income Common Stockholders | - | -19.08 | -22.26 | -19 | -28.87 |
| Net Income Including Noncontrolling Interests | - | -19.08 | -22.26 | -19 | -26.44 |
| Normalized Income | - | -19.08 | -22.26 | -19 | -26.44 |
| Diluted NI Availto Com Stockholders | - | -19.08 | -22.26 | -19 | -28.87 |
| Basic Average Shares | 12.72 | 12.66 | 15.56 | 17.11 | - |
| Diluted Average Shares | 12.72 | 12.66 | 15.56 | 17.11 | - |
| General And Administrative Expense | - | 6.01 | 7.52 | 6.93 | 9.42 |
| Other Gand A | - | 3.07 | 4.38 | 4.23 | 6.40 |
| Salaries And Wages | - | 1.76 | 2.30 | 2.09 | 2.42 |
| Insurance And Claims | - | 1.18 | 0.84 | 0.61 | 0.60 |
| Otherunder Preferred Stock Dividend | - | - | - | 0 | 2.43 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Nuvectis Pharma, Inc.this co. | NVCT | $257M | -9.70 | 13.93 | -143.6% | - |
| Entrada Therapeutics, Inc. | TRDA | $272M | -1.89 | 0.89 | -47.0% | -1.51 |
| Anavex Life Sciences Corp. | AVXL | $261M | -5.63 | 2.75 | -48.9% | - |
| Akebia Therapeutics, Inc. | AKBA | $260M | -48.70 | 7.98 | -16.4% | 5.86 |
| Fate Therapeutics, Inc. | FATE | $258M |
| - |
| - |
| - |
| - |
| -1.89 |
| 1.24 |
| -65.8% |
| -2.14 |
| Codexis, Inc. | CDXS | $255M | -5.79 | 5.04 | -87.0% | -8.18 |
| Sight Sciences, Inc. | SGHT | $250M | -6.51 | 3.91 | -60.1% | -6.07 |
| Protara Therapeutics, Inc. | TARA | $248M | -4.32 | 1.26 | -29.2% | -3.14 |
| Coherus Oncology, Inc. | CHRS | $243M | 1.45 | 3.98 | 275.4% | -1.14 |
| Peer Median | - | -4.98 | 3.33 | -47.9% | -2.14 | |